Literature DB >> 16687221

Preparation of silymarin proliposome: a new way to increase oral bioavailability of silymarin in beagle dogs.

Xiao Yan-yu1, Song Yun-mei, Chen Zhi-peng, Ping Qi-neng.   

Abstract

The aim of the present study was to find a method to increase oral bioavailability of silymarin, that is to say, by the preparation of silymarin proliposome and to compare the pharmacokinetic characteristics and bioavailability after oral administration of silymarin proliposome and silymarin in beagle dogs. Silymarin proliposome was prepared by the film-deposition on carriers. After the proliposome was contacted with water, the silymarin liposome suspensions formed automatically. The tests of physicochemical properties including SEM, TEM, encapsulation efficiency, dissolution studies, particle size of the reconstituted liposome and stability of the silymarin proliposome were determined by laser-particle-sizer, HPLC, etc. The concentrations of silymarin in plasma of beagle dogs and its pharmacokinetic behaviors after oral administration of silymarin liposome suspensions and silymarin were studied by RP-HPLC. The pharmacokinetic parameters were computed by software program 3p97. The encapsulation efficiency of silymarin liposome could be more than 90%, with an average particle size of about 196.4 nm and the proliposome appeared a very stability at 40 degrees C during 3 months. It was found that mean plasma concentration-time curves of silymarin after oral administration of liposome suspensions and silymarin in beagle dogs were both in accordance with open two-compartments model and first-order absorption. Pharmacokinetic parameters of silymarin proliposome and silymarin in beagle dogs were Tmax both 30 min; Cmax 472.62 and 89.78 ng mL(-1); and AUC0-infinity 2606.21 and 697 ng mL(-1)h, respectively. The high bioavailability of silymarin proliposome could be obtained by oral administration. Silymarin proliposome was stable and did enchance the gastrointestinal absorption of silymarin.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16687221     DOI: 10.1016/j.ijpharm.2006.03.037

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  16 in total

1.  Development of silymarin self-microemulsifying drug delivery system with enhanced oral bioavailability.

Authors:  Xinru Li; Quan Yuan; Yanqing Huang; Yanxia Zhou; Yan Liu
Journal:  AAPS PharmSciTech       Date:  2010-04-20       Impact factor: 3.246

2.  In vitro and in vivo evaluation of proniosomes containing celecoxib for oral administration.

Authors:  Mohamed Nasr
Journal:  AAPS PharmSciTech       Date:  2010-01-08       Impact factor: 3.246

3.  Proliposomes for oral delivery of dehydrosilymarin: preparation and evaluation in vitro and in vivo.

Authors:  Chang Chu; Shan-shan Tong; Ying Xu; Li Wang; Min Fu; Yan-ru Ge; Jiang-nan Yu; Xi-ming Xu
Journal:  Acta Pharmacol Sin       Date:  2011-06-13       Impact factor: 6.150

4.  Apoptosis induction and anti-cancer activity of LeciPlex formulations.

Authors:  Vivek V Dhawan; Ganesh V Joshi; Ankitkumar S Jain; Yuvraj P Nikam; Rajiv P Gude; Rita Mulherkar; Mangal S Nagarsenker
Journal:  Cell Oncol (Dordr)       Date:  2014-09-10       Impact factor: 6.730

5.  Formulation Development and in vitro Characterization of Proliposomes for Topical Delivery of Aceclofenac.

Authors:  Vandana Gupta; Ashok K Barupal; Suman Ramteke
Journal:  Indian J Pharm Sci       Date:  2008-11       Impact factor: 0.975

6.  Recent advances in nanoparticle formulation of oleanolic acid.

Authors:  Meiwan Chen; Zhangfeng Zhong; Wen Tan; Shengpeng Wang; Yitao Wang
Journal:  Chin Med       Date:  2011-05-27       Impact factor: 5.455

7.  Hyperoside, a flavonoid compound, inhibits proliferation and stimulates osteogenic differentiation of human osteosarcoma cells.

Authors:  Ning Zhang; Mei-Dan Ying; Yong-Ping Wu; Zhi-Hong Zhou; Zhao-Ming Ye; Hang Li; Ding-Sheng Lin
Journal:  PLoS One       Date:  2014-07-01       Impact factor: 3.240

8.  Calycosin-loaded nanoliposomes as potential nanoplatforms for treatment of diabetic nephropathy through regulation of mitochondrial respiratory function.

Authors:  Chunrong Huang; Lian-Fang Xue; Bo Hu; Huan-Huan Liu; Si-Bo Huang; Suliman Khan; Yu Meng
Journal:  J Nanobiotechnology       Date:  2021-06-13       Impact factor: 10.435

Review 9.  Can formulation and drug delivery reduce attrition during drug discovery and development-review of feasibility, benefits and challenges.

Authors:  S Basavaraj; Guru V Betageri
Journal:  Acta Pharm Sin B       Date:  2014-01-24       Impact factor: 11.413

10.  Bioavailability of polyphenol liposomes: a challenge ahead.

Authors:  Nathalie Mignet; Johanne Seguin; Guy G Chabot
Journal:  Pharmaceutics       Date:  2013-09-17       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.